Vapotherm Inc (PK:VAPO)
Business Focus: Advanced Medical Equipment & Technology
Feb 22, 2024 03:10 pm ET
Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
EXETER, N.H., Feb. 22, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), today announced fourth quarter and fiscal year 2023 financial results and related highlights.
Dec 15, 2023 07:00 am ET
OTC Markets Group Welcomes Vapotherm, Inc. to OTCQX
OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Vapotherm, Inc. (OTCQX: VAPO), a global medical technology company specializing in the development and...
Dec 14, 2023 05:27 pm ET
Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQX
EXETER, N.H., Dec. 14, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determined to suspend trading of – and commence proceedings to delist – shares of the Company's common stock, effective immediately. This suspension was made because the Company fell below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15 million.
Dec 11, 2023 05:45 am ET
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQX
EXETER, N.H., Dec. 11, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced its intention to voluntarily delist its common stock from The New York Stock Exchange ("NYSE") and its filing of an application to have its common stock quoted on the OTCQX Marketplace ("OTCQX").
Nov 28, 2023 03:54 pm ET
Vapotherm Educates over 8,000 Clinicians in Respiratory Care Month
EXETER, N.H., Nov. 28, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress is excited to announce the participation of over 8,000 clinicians in interactive, digital based, evidence based education focused on a variety of respiratory clinical topics. The education was free to clincians in celebration of Respiratory Care Week, and continued through the month of October c
Nov 08, 2023 03:10 pm ET
Vapotherm Reports Third Quarter 2023 Financial Results
EXETER, N.H., Nov. 8, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced third quarter 2023 financial results and related highlights.
Nov 01, 2023 06:45 am ET
Vapotherm To Report Third Quarter 2023 Financial Results
EXETER, N.H., Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Oct 04, 2023 06:45 am ET
Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulas
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced the online publication of “Validation of Human Upper Computational Fluid Dynamics Model for Turbulent Mixing” in the Journal of Fluid Dynamics. The full article will be published in the December issue of J. Fluids Engineering. Computational fluid dynamics uses advanced computer algorithms to understand gas flo
Sep 25, 2023 06:45 am ET
Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced the presentation of an Investigator-initiated clinical trial, “High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility randomized controlled trial” at the European Respiratory Society International Congress 2023. The study was conducted through the Brighton and Sussex Clinic
Aug 08, 2023 04:10 pm ET
Vapotherm Reports Second Quarter 2023 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced second quarter 2023 financial results.
Jul 25, 2023 04:30 pm ET
Vapotherm To Report Second Quarter 2023 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
May 03, 2023 04:10 pm ET
Vapotherm Reports First Quarter 2023 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2023 financial results.
Apr 27, 2023 04:30 pm ET
Vapotherm To Report First Quarter 2023 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Mar 17, 2023 04:30 pm ET
Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it was notified (the “Notice”) on March 15, 2023 by the New York Stock Exchange, Inc. (the “NYSE”) that the Company is not in compliance with the NYSE’s continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual because the average closing price of the Co
Feb 23, 2023 04:15 pm ET
Vapotherm Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced fourth quarter and fiscal year 2022 financial results.
Feb 14, 2023 04:15 pm ET
Vapotherm Announces Closing of $23 Million Private Placement
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it closed its previously announced private placement on February 10, 2023, for the issuance and sale of 17,502,244 shares of its common stock and pre-funded warrants to purchase up to 4,402,508 shares of its common stock. The pre-funded warrants have a term of 30 years and an exercise pr
Feb 08, 2023 06:50 am ET
Vapotherm Announces $23 Million Private Placement
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with a select group of institutional and accredited investors through a private placement financing (“PIPE”) for gross proceeds of approximately $23.0 million, before deducting fees to the placement agent and
Feb 08, 2023 06:45 am ET
Vapotherm Reports Preliminary Fourth Quarter and Full Year 2022 Results and Year-End Cash Balance
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced preliminary unaudited fourth quarter and full year 2022 net results.
Dec 09, 2022 07:39 am ET
Thinking about buying stock in Baudax Bio, Zhihu, Vapotherm, Kingsoft Cloud, or Summit Therapeutics?
NEW YORK, Dec. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BXRX, ZH, VAPO, KC, and SMMT.
Dec 07, 2022 04:05 pm ET
Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder
Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the...
Dec 06, 2022 04:30 pm ET
Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it was notified (the “Notice”) on November 30, 2022 by the New York Stock Exchange, Inc. (the “NYSE”) that the Company is not in compliance with the NYSE’s continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual because the average closing price of the
Dec 06, 2022 07:32 am ET
Thinking about buying stock in COMSovereign, Vivint Smart Home, Tilray, Otonomy, or Vapotherm?
NEW YORK, Dec. 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for COMS, VVNT, TLRY, OTIC, and VAPO.
Nov 22, 2022 06:55 am ET
Vapotherm Announces Amendment to Debt Agreement
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that, on November 21, 2022, the Company entered into Amendment No. 3 to its Loan and Security Agreement (the “Third Amendment,” with SLR Investment Corp. (“SLR”), as Collateral Agent, and the lenders party thereto.
Nov 02, 2022 04:10 pm ET
Vapotherm Reports Third Quarter 2022 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced third quarter 2022 financial results.
Oct 26, 2022 04:30 pm ET
Vapotherm to Report Third Quarter 2022 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Wednesday, November 2, 2022. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Oct 03, 2022 04:30 pm ET
Vapotherm Announces Debt Amendment and NYSE Continued Listing Standard Notice
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that, on September 30, 2022, the Company entered into an Amendment No. 2 to Loan and Security Agreement (the “Second Amendment,” together with the Loan and Security Agreement, the “Amended Loan and Security Agreement”) with SLR Investment Corp., as Collateral Agent, and the lenders party ther
Aug 04, 2022 04:30 pm ET
Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 via webcast.
Aug 03, 2022 04:10 pm ET
Vapotherm Reports Second Quarter 2022 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced second quarter 2022 financial results.
Jul 20, 2022 04:30 pm ET
Vapotherm to Report Second Quarter 2022 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Wednesday, August 3, 2022. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Jun 01, 2022 04:15 pm ET
Vapotherm to Participate in the William Blair 42nd Annual Growth Stock Conference
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the William Blair 42nd Annual Growth Stock Conference on Monday, June 6, 2022.
May 04, 2022 04:10 pm ET
Vapotherm Reports First Quarter 2022 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2022 financial results.
May 02, 2022 08:30 am ET
Vapotherm to Report First Quarter 2022 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Wednesday, May 4, 2022. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Apr 06, 2022 04:30 pm ET
Vapotherm Announces Preliminary Revenue for First Quarter of 2022 and Withdraws 2022 Annual Guidance
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today announced preliminary unaudited revenue for the quarter ended March 31, 2022. The Company also announced withdrawal of its full year 2022 revenue guidance (issued on January 12, 2022 and reiterated on February 24, 2022) together with its full year 2022 gross margin, operating expense and adjusted EBITDA guidance.
Mar 03, 2022 04:15 pm ET
Vapotherm Launches Strategic Partnership with Carnegie Mellon University to Deliver a Tailored Artificial Intelligence (AI) Program to Drive Better Outcomes for Patients Suffering from Chronic Respira
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on developing innovative, non-invasive technologies and digital health solutions for respiratory patients, today announced a strategic partnership with Carnegie Mellon University, a world class AI research institution, to deliver a tailored artificial intelligence (AI) program for Vapotherm employees. The aim of the AI program, named Vapotherm AI for Business, is to tap into Carnegie Mellon’s AI expertise to provide a customized training program for Vapotherm employees that incorporates the use of AI to deliver be
Feb 24, 2022 04:10 pm ET
Vapotherm Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders today announced fourth quarter and fiscal year 2021 financial results.
Feb 10, 2022 04:30 pm ET
Vapotherm to Report Fourth Quarter and Full Year 2021 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders, today announced that it will release financial results for the fourth quarter and full year 2021 after the close of trading on Thursday, February 24, 2022. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Jan 12, 2022 06:45 am ET
Vapotherm Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders today announced preliminary unaudited fourth quarter and full year 2021 net revenue results.
Nov 22, 2021 08:30 am ET
Vapotherm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced the company will be participating in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.
Nov 03, 2021 04:10 pm ET
Vapotherm Reports Third Quarter 2021 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company, today announced third quarter 2021 financial results.
Oct 20, 2021 04:30 pm ET
Vapotherm to Report Third Quarter 2021 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Wednesday, November 3, 2021. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Sep 08, 2021 06:55 am ET
Vapotherm Increases Fiscal Year 2021 Revenue Outlook and Announces Expansion of Production Capacity
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today updated its fiscal year 2021 revenue expectations and announced it will expand its disposables production capacity. The expansion of disposables production capacity will include the addition of assembly lines in Mexico which will increase capacity by 75% without adding material fixed costs and prepare the Company for the possibility that COVID-19 becomes a permanent part of the respiratory landscape like flu and RSV. This expansion will diversify the Company’s manufacturing base and is an element of its gross margin improvement
Aug 30, 2021 06:00 am ET
Vapotherm Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0. This next generation system is designed to provide high velocity therapy using an integrated air source, eliminating the need for wall air or any pressurized air source. It is estimated that 50% of U.S. hospital beds don’t have wall air. When paired with an oxygen source, the HVT 2.0 will support patients whether they need respiratory support in the hospital or home setting. The Company is planning a limited commercial release of H
Aug 09, 2021 04:10 pm ET
Vapotherm Reports Second Quarter 2021 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced second quarter 2021 financial results.
Jul 28, 2021 04:30 pm ET
Vapotherm to Participate in the Canaccord Genuity 41st Annual Growth Conference
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 via webcast.
Jul 21, 2021 04:30 pm ET
Vapotherm to Report Second Quarter 2021 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Monday, August 9, 2021. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Jun 09, 2021 04:30 pm ET
Vapotherm to Host First Investor Day
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be hosting their first investor day on Wednesday, June 23, 2021 beginning at 10:00AM ET.
May 25, 2021 07:15 am ET
Vapotherm to Participate in the William Blair 41st Annual Growth Stock Conference
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021 via webcast.
May 06, 2021 06:45 am ET
Vapotherm to Participate in the Bank of America Securities 2021 Health Care Conference
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Bank of America Securities 2021 Health Care Conference on Wednesday, May 12, 2021 via webcast.
May 05, 2021 04:10 pm ET
Vapotherm Reports First Quarter 2021 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced first quarter 2021 financial results.
Apr 21, 2021 05:53 pm ET
Vapotherm to Report First Quarter 2021 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2021 after the close of trading on Wednesday, May 5, 2021. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Feb 24, 2021 04:01 pm ET
Vapotherm Reports Fourth Quarter and Fiscal Year 2020 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat Patients of all ages suffering from respiratory distress, today announced fourth quarter and fiscal year 2020 financial results.
Feb 12, 2021 07:00 am ET
Vapotherm to Participate in Fireside Chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in a Fireside Chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Wednesday, February 17, 2021 via webcast.
Feb 10, 2021 04:01 pm ET
Vapotherm to Report Fourth Quarter and Fiscal Year 2020 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the fourth quarter and fiscal year 2020 after the close of trading on Wednesday, February 24, 2021. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Jan 13, 2021 06:00 am ET
Vapotherm Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced certain preliminary unaudited fourth quarter and full year 2020 revenue results.
Jan 07, 2021 04:01 pm ET
Vapotherm to Present at the 23rd Annual ICR/Westwicke Conference
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the 23rd Annual ICR/Westwicke Conference on Thursday, January 14, 2021 via webcast.
Dec 04, 2020 08:00 am ET
Vapotherm Wins Prestigious Zenith Award from American Association for Respiratory Care for Support of Respiratory Therapists
Vapotherm, Inc. (NYSE:VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® systems, has been awarded the prestigious American Association for Respiratory Care Zenith Award.
Dec 01, 2020 04:01 pm ET
Vapotherm Updates Its Fourth Quarter and Fiscal Year 2020 Outlook
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced an update to its fourth quarter and fiscal year 2020 revenue guidance given on November 4, 2020.
Nov 04, 2020 04:01 pm ET
Vapotherm Reports Third Quarter 2020 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced third quarter 2020 financial results.
Oct 23, 2020 04:01 pm ET
Vapotherm Announces Appointment of Donald Spence to Board of Directors and the Resignations of Craig Reynolds and Geoff Pardo
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced the appointment of Donald Spence to the Company’s Board of Directors. Mr. Spence will serve as a member and chair of the Compensation Committee, and as a member of the Audit Committee. The Board of Directors unanimously voted to appoint Mr. Spence to fill these positions, effective October 21, 2020.
Oct 22, 2020 04:05 pm ET
Vapotherm Announces Closing of Debt Refinancing
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that it has entered into a loan and security agreement with CIBC Innovation Banking that provides the Company with up to $52 million in debt financing through a combination of a term loan facility and a revolving credit facility. Proceeds of the facilities will be used to repay the Company’s existing revolving lo
Oct 21, 2020 04:05 pm ET
Vapotherm to Report Third Quarter 2020 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of Vapotherm’s proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Wednesday, November 4, 2020. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Aug 12, 2020 08:45 am ET
New ‘Negative Pressure Scavenger Kit’ Helps Hospitals Manage Infectious Particles When Treating Patients with COVID-19, Supports Non-Profits Supporting COVID-19 Front-Line Clinicians
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced the release of a low-cost, easy to use kit to help clinicians create a zone of relative negative pressure at the patient's face which may mitigate the risk of transmission of potentially infectious particles while treating COVID-19 patients. All profits from the kits will be distributed to non-profit organizations supporting front-line clinicia
Aug 06, 2020 04:01 pm ET
Vapotherm to Present at the Canaccord Genuity 40th Annual Growth Conference
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 via webcast.
Aug 04, 2020 04:01 pm ET
Vapotherm Reports Second Quarter 2020 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced second quarter 2020 financial results.
Jul 21, 2020 04:01 pm ET
Vapotherm to Report Second Quarter 2020 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of Vapotherm’s proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2020 after the close of trading on Tuesday, August 4, 2020. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Jun 04, 2020 07:00 am ET
Vapotherm to Expand Production Capacity in Advance of Potential Increase in Demand for High-Flow Nasal Cannula Systems for Treating COVID-19 Respiratory Distress
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients suffering from respiratory distress, today announced a major expansion in its capital equipment manufacturing capabilities. This expansion is expected to enable the company to increase production of its Precision Flow® systems by up to 20X above pre-COVID-19 pandemic levels. At maximum capacity, Vapotherm’s manufacturing increase would create up to an additional 350 manufacturing jobs at its New Hampshi
Jun 03, 2020 07:00 am ET
Vapotherm to Present at the William Blair 40th Annual Growth Stock Conference
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020 via webcast.
May 11, 2020 07:00 am ET
Vapotherm to Present at the Bank of America Securities Virtual Health Care Conference 2020
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the Bank of America Securities Health Care Conference 2020 on Thursday, May 14, 2020 via webcast.
May 06, 2020 10:50 pm ET
Vapotherm Announces Pricing of Public Offering of Common Stock
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the pricing of an underwritten public offering of 3,350,000 shares of its common stock at a price to the public of $26.00 per share. In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares of its common stock at the public offering price less underwriting discounts an
May 06, 2020 04:08 pm ET
Vapotherm Announces Proposed Public Offering of Common Stock
Vapotherm, Inc. (NYSE:VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of $75 million of its shares of common stock. All of the shares will be offered by Vapotherm. Vapotherm also expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15 percent of the number of shares sold in the offerin
May 05, 2020 04:02 pm ET
Vapotherm Reports First Quarter 2020 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced first quarter 2020 financial results.
Apr 21, 2020 04:05 pm ET
Vapotherm to Report First Quarter 2020 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2020 after the close of trading on Tuesday, May 5, 2020. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Apr 13, 2020 07:00 am ET
Vapotherm Reports Preliminary First Quarter 2020 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced certain preliminary first quarter of 2020 financial results.
Apr 09, 2020 06:00 am ET
FDA Grants Vapotherm® Oxygen Assist Module (OAM™) Breakthrough Device Designation
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that the U.S. Food and Drug Administration (FDA) recently granted Breakthrough Device Designation for the Company’s Oxygen Assist Module (OAM).
Mar 24, 2020 09:31 am ET
Thinking about buying stock in Pinterest, Planet Fitness, Sealed Air, Tilray, or Vapotherm?
NEW YORK, March 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PINS, PLNT, SEE, TLRY, and VAPO.
Mar 23, 2020 05:06 pm ET
Vapotherm Provides Business Update in Response to COVID-19 Pandemic
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced an update on their business in response to the COVID-19 pandemic.
Mar 16, 2020 09:31 am ET
Thinking about buying stock in Advanced Micro Devices, Bank of America, OpGen, Target, or Vapotherm?
NEW YORK, March 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, BAC, OPGN, TGT, and VAPO.
Mar 04, 2020 04:01 pm ET
Vapotherm Reports Fourth Quarter and Fiscal Year 2019 Financial Results
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced fourth quarter and fiscal year 2019 financial results.
Feb 19, 2020 04:02 pm ET
Vapotherm to Report Fourth Quarter and Fiscal Year 2019 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the fourth quarter and fiscal year 2019 after the close of trading on Wednesday, March 4, 2020. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Feb 05, 2020 04:01 pm ET
Vapotherm® Receives CE Mark for Oxygen Assist Module in the European Union
Vapotherm, Inc. (NYSE: VAPO) today announced that it has received the CE Mark for its Vapotherm Oxygen Assist Module (OAM). When used with a Precision Flow® system, the Vapotherm OAM helps clinicians keep their patients within the target oxygen saturation range more effectively than with manual control alone. Keeping babies in the prescribed oxygen saturation range may reduce the health risks associated with dosing too much, or too little oxygen – such as visual or developmental impairment in premature infants.
Jan 30, 2020 04:02 pm ET
Vapotherm Announces Appointment of Lance Berry to Board of Directors and the Retirement of Neal Armstrong
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced the appointment of Lance Berry to its Board of Directors, and as a member and chair of the Audit Committee, both effective on January 29, 2020. Mr. Berry replaces Neal Armstrong, whose retirement was effective upon Mr. Berry’s appointment.
Jan 10, 2020 06:00 am ET
Vapotherm Reports Preliminary Fourth Quarter and Fiscal Year 2019 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced certain preliminary unaudited fourth quarter and full year 2019 revenue results.
Nov 05, 2019 04:01 pm ET
Vapotherm Reports Third Quarter 2019 Financial Results
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced its financial and operating results for the third quarter ended September 30, 2019.
Nov 01, 2019 04:30 pm ET
New Study Shows Vapotherm Hi-VNI® Technology Improved In-patient Participant Ambulation Recovery Time by 32.5% Versus Standard Oxygen Therapy
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology, today announced that a paper published in the Journal of Clinical Respiratory Diseases and Care, titled “Assessing the Clinical Effect of High Velocity Nasal Insufflation on Improving Ambulation in Patients with Dyspnea: A Feasibility Study” demonstrated that use of Vapotherm Hi-VNI Technology during ambulation is feasible and showed that patients with dyspnea participating in this study who used Hi-VNI Technology as respiratory support walke
Oct 15, 2019 04:02 pm ET
Vapotherm to Report Third Quarter 2019 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today that it will release financial results for the third quarter of 2019 after the close of trading on Tuesday, November 5, 2019. Vapotherm’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Aug 01, 2019 07:41 pm ET
Vapotherm Announces Pricing of Public Offering of Common Stock
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the pricing of its public offering of 3,105,000 shares of its common stock at a price to the public of $14.50 per share. All of the shares will be offered by Vapotherm. In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 465,750 shares of its common stock at the public offering
Jul 30, 2019 04:11 pm ET
Vapotherm Announces Proposed Public Offering of Common Stock
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of 2,600,000 shares of its common stock. All of the shares will be offered by Vapotherm. Vapotherm also expects to grant the underwriters a 30-day option to purchase up to an additional 390,000 shares of common stock.
Jul 29, 2019 04:01 pm ET
Vapotherm Reports Second Quarter 2019 Financial Results
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced its financial and operating results for the second quarter ended June 30, 2019.
Jul 08, 2019 04:02 pm ET
Vapotherm to Report Second Quarter 2019 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today that it will release financial results for the second quarter of 2019 after the close of trading on Monday, July 29, 2019. Vapotherm’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
May 24, 2019 04:30 pm ET
Vapotherm to Present at the William Blair 39th Annual Growth Stock Conference
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company
focused on the development and commercialization of its proprietary
Hi-VNI® Technology products that are used to treat patients of all ages
suffering from respiratory distress, today announced that its management
team will be presenting at the William Blair 39th Annual Growth Stock
Conference on Wednesday, June 5th at the Loews Chicago Hotel
in Chicago, Illinois.
May 10, 2019 05:01 pm ET
Vapotherm to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company
focused on the development and commercialization of its proprietary
Hi-VNI® Technology products that are used to treat patients of all ages
suffering from respiratory distress, today announced that its management
team will be presenting at the Bank of America Merrill Lynch 2019 Health
Care Conference on Wednesday, May 15 at the Encore Hotel in Las Vegas,
Nevada.
May 07, 2019 04:01 pm ET
Vapotherm Reports First Quarter 2019 Financial Results
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company
focused on the development and commercialization of its proprietary
Hi-VNI® Technology products that are used to treat patients of all ages
suffering from respiratory distress, today announced its financial and
operating results for the first quarter ended March 31, 2019.
Apr 17, 2019 07:30 am ET
Vapotherm to Report First Quarter 2019 Financial Results
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology
company focused on the development and commercialization of its
proprietary Hi-VNI® Technology products that are used to treat patients
of all ages suffering from respiratory distress, announced today that it
will release financial results for the first quarter of 2019 after the
close of trading on Tuesday, May 7, 2019. Vapotherm’s management team
will host a corresponding conference call beginning at 4:30 p.m. ET to
discuss the financial results and recent business developm
Mar 26, 2019 07:30 am ET
Emergency Department Subgroup Study Showed Hi-VNI® Technology Had Similar Outcomes to Non-invasive Positive Pressure Ventilation in Management of Respiratory Distress Among Acute Decompensated Heart F
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company
focused on the development and commercialization of its proprietary
Hi-VNI® Technology, today announced that a paper published in the American
Journal of Emergency Medicine, titled “HVNI vs NIPPV in the
treatment of Acute Decompensated Heart Failure: subgroup analysis of a
multi-center trial in the ED” showed equivalent outcomes between Hi-VNI
Technology and Non-invasive Positive Pressure Ventilation (NiPPV) in the
treatment of respiratory distress in a subgroup of patients
Mar 12, 2019 04:13 pm ET
Vapotherm Reports Fourth Quarter and Fiscal Year 2018 Financial Results
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company
focused on the development and commercialization of its proprietary
Hi-VNI® Technology products that are used to treat patients of all ages
suffering from respiratory distress, announced today fourth quarter and
fiscal year 2018 financial results.
Feb 13, 2019 07:30 am ET
Vapotherm® Releases Next Generation of Capital Unit: Precision Flow Hi-VNI™ System
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company
focused on the development and commercialization of its proprietary
Hi-VNI® Technology products that are used to treat patients
of all ages suffering from respiratory distress, today announced the
release of the next generation of its capital unit: the Precision Flow
Hi-VNI system. For this generation of the Precision Flow®
system, both the hardware and software have been updated to improve
reliability, and to comply with the EMC 4th Edition
Dec 24, 2018 07:30 am ET
Vapotherm to be Added to the Russell 2000®, 3000® and Microcap® Indexes
Vapotherm, Inc. (NYSE: VAPO) announced today that it has been added to
the Russell 2000®, Russell 3000® and
Russell Microcap® Indexes, effective after market
close on December 21, 2018, as part of Russell’s quarterly addition of
companies with recent initial public offerings.
Dec 04, 2018 08:00 am ET
Clinical Study Shows Vapotherm’s New IntellO2™ Module for Precision Flow® System Significantly Improves Maintenance of Premature Neonates in Target Oxygenation Range
Vapotherm, Inc. today announced the publication of a key prospective,
multi-center, controlled, order-randomized crossover trial. The study
demonstrates that using the IntellO2 automated oxygen
controller module helped clinicians maintain neonates in the
physician-prescribed oxygen saturation range significantly better than
manual control alone.
Nov 16, 2018 11:58 am ET
Vapotherm Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology
company focused on the development and commercialization of its
proprietary Hi-VNI® Technology products that are used to
treat patients of all ages suffering from respiratory distress, today
announced the closing of its initial public offering of 4,600,000 shares
of common stock, at a price to the public of $14.00 per share, which
includes the exercise in full by the underwriters of their option to
purchase up to an additional 600,000 shares of common stock. The g
Nov 13, 2018 08:48 pm ET
Vapotherm Announces Pricing of Initial Public Offering
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology
company focused on the development and commercialization of its
proprietary Hi-VNI® Technology products that are used to
treat patients of all ages suffering from respiratory distress,
announced the pricing of its initial public offering of 4,000,000 shares
of common stock at a price to the public of $14.00 per share. In
addition, Vapotherm has granted the underwriters a 30-day option to
purchase up to an additional 600,000 shares of common stock, at the
in
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.